• Solid revenue growth in the first half of 2025 of +5.6% at constant exchange rates and scope

• Adjusted recurring operating income² of 18.3% as a ratio to revenue, in line with our expectations

  • Down compared to 2024 due to phasing and non-recurring effects

• 2025 targets confirmed

  • Revenue growth expected between 4% and 6% at constant rates and scope

  • Adjusted recurring operating income¹ expected around 16%

Our team, responsible for drug registration and maintaining and defending Marketing Authorizations (MAs), is ready to reveal what they do.

In the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation

In the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation

Because the biology professions are constantly evolving, we provide our teams with the highest level of skills in vaccine production. The Bio Academy, our in-house training centre, aims to integrate, develop and maintain these profiles at the cutting edge of technology and regulation.

Since the end of May, our Virbac teams in Thailand have achieved a decisive milestone for swine health. We now offer farmers two complementary oral vaccines specifically designed to prevent post-weaning diarrhea (PWD) and edema disease (ED) in piglets caused by F4 and F18 factors. These solutions enrich our global range and underscore our strong commitment to a preventive approach in livestock farming.

A cornerstone of our company's identification and differentiation, the Virbac logo is adapting to current standards.

Virbac Hellas is proud to celebrate the 20th anniversary of its presence in Greece. Over the past two decades, Virbac Hellas has established itself as a trusted partner for veterinarians, farmers, and pet owners, driven by a commitment to innovation, collaboration, and animal well-being.

Following a call for tenders from ENABEL, the Belgian development cooperation agency, we conducted a scoping study to optimize biosecurity and environmental practices in aquaculture in Rwanda. This project culminated in late 2024 with a reference document for the Rwandan government and fish farmers.

Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025.

Aware of the specific health challenges in each territory, we adapt our offerings to meet the needs of breeders and veterinarians. As of April 2025, our new combined vaccine against porcine parvovirus and leptospirosis is available in France, where both diseases pose significant health challenges.

Ten years after its launch, our Veterinary HPM^® physiological food range is being revamped and will be progressively rolled out, starting in Europe from May 2025, to better meet the changing expectations of veterinarians and pet owners. Our commitment, however, remains the same: to advance animal health through high-quality nutrition, based on science and innovation.

Launched a few months ago in around ten European countries, DIOD (Digital Interactive Otitis Drawings) is our new interactive digital tool. It allows for the modeling of all types of otitis, supporting explanations provided to pet owners and optimizing patient management. Developed by our teams, it further enriches our DailyDerma program, which assists with daily veterinary dermatology practice.

Discover the press release issued on April 16, 2025.

In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope

Following a scientific pre-launch in December 2024, our Japanese teams officially presented our antimicrobial-free solution at the annual congress of the Japanese Society of Veterinary Dermatology, held on March 8th and 9th in Tokyo. Recommended as a first-line treatment for canine acute erythemato-ceruminous otitis externa, even with microbial proliferation, our approach offers an effective and safe alternative.

●    Very strong revenues increase of 13.6% at constant exchange rates, driven by:
      ○  dynamic organic growth (+7.5%) 
      ○  strategic contribution of our acquisitions (+6.1%)

●    2024 operating income2 at an all-time high of 16.6% of revenues (16.0% excluding
      acquisitions)
      ○  up by 1.5 percentage points compared to 2023 

●    Positive trend for 2025
      ○  sales growth expected between 4% and 6% at constant exchange rates and scope
      ○  operating income relatively stable at around 16%, excluding the impact of acquisitions

Our new Veterinary HPM^® digestive support wet foods have been specially designed to meet the specific needs of dogs and cats suffering from digestive disorders. Gradually available in Europe since January, they help our companions regain a better quality of daily life and facilitate their nutritional recovery in case of convalescence.

Our endocrinology offering expands with a unique solution for treating Cushing's syndrome in dogs. Available for several months in Europe, it simplifies the daily management of this hormonal disease and improves the animal's well-being.

In January, we launched four new cattle vaccines designed to protect bovines at various stages of their growth against respiratory and reproductive challenges. This marks another milestone in our ongoing commitment to expand our offering of preventive solutions for healthier herds to veterinarians and farmers in the US.

Our teams are strengthening our swine vaccine solutions to better address the local challenges faced by professionals. Available since the end of 2024 in Germany, January 2025 in France, and soon in Austria, this new broad-spectrum vaccine allows, through the vaccination of pregnant sows, passive immunization of newborn piglets against the main pathogens responsible for neonatal diarrhea.

Our American teams have worked tirelessly alongside Emmyon, Inc. to offer an innovative ursolic acid-based solution that supports muscle health in dogs. Full details of this partnership and the resulting product can be found in the press release issued on January 07, 2025. 

Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)

Since October, our French teams have been offering Day 1, a new application that allows French veterinarians and farmers to monitor and compare colostrum quality on the farm. A valuable decision-making aid to improve herd health!

Discover the video of Habib Ramdani wishes to all Virbac teams worldwide. 

In 2024, two of our fourteen Great Place To Work^®-certified subsidiaries were recognized in the Best Workplaces^® rankings. These distinctions reflect our commitment to creating inclusive, fulfilling, and trust-based work environments.

In line with our code of conduct, the business partner charter, a revisited version of our supplier code, applies to all our business partners worldwide.

On December 2, we finalized the acquisition of Turkish company Mopsan, specialized in the distribution of petfood and companion animal health products.

Our program, already available to pet veterinarians since 2023,  will also be available to farm animal veterinarians worldwide during 2025. With Let's do it smart, we offer them concrete tools for choosing pest control solutions tailored to the real needs of each farm. This helps preserve the fragile balance between man, animal and ecosystem.

In 2024, we launched several major industrial projects at our original site in Carros. More than just a local presence, we are investing to make this site a true center of excellence and a pillar of our future growth.